Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate

Journal of Hepatology

Volumn 61, Issue 6, 2014, Pages 1228-1237

  Marcellin, Patrick ^a   Buti, Maria ^b   Krastev, Zahari ^c   De Man, Robert A ^d   Zeuzem, Stefan ^e   Lou, Lillian ^f   Gaggar, Anuj ^f   Flaherty, John F ^f   Massetto, Benedetta ^f   Lin, Lanjia ^f   Dinh, Phillip ^f   Subramanian, G Mani ^f   McHutchison, John G ^f   Flisiak, Robert ^g   Gurel, Selim ^h   Dusheiko, Geoffrey M ⁱ   Jenny Heathcote, E ^j  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c UNIVERSITY HOSPITAL ST IVAN RILSKI   (Bulgaria)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e Diakoniekrankenhaus   (Germany)

^f GILEAD SCIENCES   (United States)

^g MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^h ULUDAG UNIVERSITY   (Turkey)

ⁱ ROYAL FREE HOSPITAL   (United Kingdom)

^j UNIVERSITY OF TORONTO   (Canada)

more..

Author keywords

Chronic hepatitis B; Hepatitis B surface antigen; Tenofovir disoproxil fumarate

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; TENOFOVIR DISOPROXIL; VIRUS DNA; ADENINE; ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; PHOSPHONIC ACID DERIVATIVE;

ADULT; AGED; ARTICLE; DRUG EFFICACY; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREDICTIVE VALUE; PREDICTOR VARIABLE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEROCONVERSION; SEROLOGY; TREATMENT DURATION; TREATMENT RESPONSE; ADOLESCENT; ANALOGS AND DERIVATIVES; BLOOD; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENZYMOLOGY; GENETICS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; IMMUNOLOGY; LIVER; LONGITUDINAL STUDY; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADENINE; ADOLESCENT; ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DOUBLE-BLIND METHOD; FEMALE; GENOTYPE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84922789624     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.07.019     Document Type: Article

References (28)

1. European Association for the Study of the Liver EASL Clinical Practice Guidelines: management of chronic hepatitis B J Hepatol 57 2012 167 185
2. A.S. Lok, and B.J. McMahon Chronic hepatitis B: update 2009 Hepatology 50 2009 661 662
3. W.C. Li, M.R. Wang, L.B. Kong, W.G. Ren, Y.G. Zhang, and Y.M. Nan Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials BMC Infect Dis 11 2011 165
4. R. Moucari, A. Korevaar, O. Lada, M. Martinot-Peignoux, N. Boyer, and V. Mackiewicz High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study J Hepatol 50 2009 1084 1092
5. G.K. Lau, T. Piratvisuth, K.X. Luo, P. Marcellin, S. Thongsawat, and G. Cooksley Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B N Engl J Med 352 2005 2682 2695
6. P. Marcellin, E. Gane, M. Buti, N. Afdhal, W. Sievert, and I.M. Jacobson Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study Lancet 381 2013 468 475
7. P. Marcellin, E.J. Heathcote, M. Buti, E. Gane, R.A. de Man, and Z. Krastev Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B N Engl J Med 359 2008 2442 2455
8. A. Snow-Lampart, B. Chappell, M. Curtis, Y. Zhu, F. Myrick, and J. Schawalder No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus Hepatology 53 2011 763 773
9. T.T. Chang, C.L. Lai, S. Kew Yoon, S.S. Lee, H.S. Coelho, and F.J. Carrilho Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B Hepatology 51 2010 422 430
10. S.S. Kim, D. Lee, M.H. Lee, J.Y. Cheong, and S.W. Cho Association of on-treatment serum hepatitis B surface antigen level with sustained virological response to nucleos(t)ide analog in patients with hepatitis B e-antigen positive chronic hepatitis B Hepatol Res 43 2013 219 227
11. G. Papatheodoridis, J. Goulis, S. Manolakopoulos, A. Margariti, X. Exarchos, and G. Kokkonis Changes of HBsAg and interferon-inducible protein 10 serum levels in naive HBeAg-negative chronic hepatitis B patients under 4-year entecavir therapy J Hepatol 60 2014 62 68
12. R. Zoutendijk, B.E. Hansen, A.J. van Vuuren, C.A. Boucher, and H.L. Janssen Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss J Infect Dis 204 2011 415 418
13. P. Marcellin, F. Bonino, C. Yurdaydin, S. Hadziyannis, R. Moucari, and H.P. Kapprell Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients Hepatol Int 7 2013 88 97
14. Marcellin P, Piratvisuth T, Brunetto MR, Bonino F, Farci P, Yurdaydin C, et al. A finite course of peginterferon alfa-2a results in inactive chronic hepatitis B and HBsAg clearance 5 years post-treatment in patients with HBeAg-negative disease: baseline characteristics and predictive factors of long-term response. In: 60th Annual Meeting of the American Association for the Study of Liver Diseases; October 30-November 3, 2009; Boston, MA.
15. M.J. Sonneveld, V. Rijckborst, Y. Cakaloglu, K. Simon, E.J. Heathcote, and F. Tabak Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-alpha2b: relation to response and HBV genotype Antivir Ther 17 2012 9 17
16. K. Wursthorn, M. Jung, A. Riva, Z.D. Goodman, P. Lopez, and W. Bao Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients Hepatology 52 2010 1611 1620
17. Y.F. Liaw, J.D. Jia, H.L. Chan, K.H. Han, T. Tanwandee, and W.L. Chuang Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C Hepatology 54 2011 1591 1599
18. M.E. Mendy, S.J. McConkey, M.A. van der Sande, S. Crozier, S. Kaye, and D. Jeffries Changes in viral load and HBsAg and HBeAg status with age in HBV chronic carriers in The Gambia Virol J 5 2008 49
19. M.A. Loriot, P. Marcellin, E. Bismuth, M. Martinot-Peignoux, N. Boyer, and C. Degott Demonstration of hepatitis B virus DNA by polymerase chain reaction in the serum and the liver after spontaneous or therapeutically induced HBeAg to anti-HBe or HBsAg to anti-HBs seroconversion in patients with chronic hepatitis B Hepatology 15 1992 32 36
20. P. Marcellin, M. Martinot-Peignoux, M.A. Loriot, E. Giostra, N. Boyer, and V. Thiers Persistence of hepatitis B virus DNA demonstrated by polymerase chain reaction in serum and liver after loss of HBsAg induced by antiviral therapy Ann Intern Med 112 1990 227 228
21. R. Moucari, M. Martinot-Peignoux, V. Mackiewicz, N. Boyer, M.P. Ripault, and C. Castelnau Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a Antivir Ther 14 2009 1183 1188
22. A.T. Tan, S. Koh, V. Goh, and A. Bertoletti Understanding the immunopathogenesis of chronic hepatitis B virus: an Asian prospective J Gastroenterol Hepatol 23 2008 833 843
23. P. Marcellin, G.K. Lau, F. Bonino, P. Farci, S. Hadziyannis, and R. Jin Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B N Engl J Med 351 2004 1206 1217
24. J. Korenman, B. Baker, J. Waggoner, J.E. Everhart, A.M. Di Bisceglie, and J.H. Hoofnagle Long-term remission of chronic hepatitis B after alpha-interferon therapy Ann Intern Med 114 1991 629 634
25. R.G. Gish, T.T. Chang, C.L. Lai, R. de Man, A. Gadano, and F. Poordad Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naive HBeAg-positive patients with chronic hepatitis B J Viral Hepat 17 2010 16 22
26. E.H. Buster, H.J. Flink, Y. Cakaloglu, K. Simon, J. Trojan, and F. Tabak Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b Gastroenterology 135 2008 459 467
27. J.M. Lee, S.H. Ahn, H.S. Kim, H. Park, H.Y. Chang, and Y. Kim Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir Hepatology 53 2011 1486 1493
28. R. Moucari, V. Mackiewicz, O. Lada, M.P. Ripault, C. Castelnau, and M. Martinot-Peignoux Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients Hepatology 49 2009 1151 1157